ACADIA Pharmaceuticals (ACAD) Set to Post Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.1992 per share and revenue of $332.58 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.07 by $0.11. The business had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. During the same period in the prior year, the business earned $0.16 earnings per share. The firm’s quarterly revenue was up 16.4% compared to the same quarter last year. On average, analysts expect ACADIA Pharmaceuticals to post $0.64 EPS for the current fiscal year and $0.98 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $20.17 on Wednesday. ACADIA Pharmaceuticals has a 1-year low of $18.39 and a 1-year high of $30.96. The stock’s 50 day moving average price is $24.30 and its 200 day moving average price is $23.82.

Insider Buying and Selling

In related news, EVP Mark Schneyer sold 14,292 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $29.22, for a total transaction of $417,612.24. Following the completion of the transaction, the executive vice president directly owned 67,828 shares in the company, valued at $1,981,934.16. The trade was a 17.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 36,699 shares of company stock valued at $1,019,894. Corporate insiders own 26.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. TD Cowen reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 24th. Royal Bank Of Canada lowered their price target on shares of ACADIA Pharmaceuticals from $37.00 to $36.00 and set an “outperform” rating on the stock in a research note on Thursday, October 8th. Citigroup reaffirmed a “buy” rating and set a $33.00 price target (down from $40.00) on shares of ACADIA Pharmaceuticals in a research note on Friday, September 25th. Citizens Jmp cut their price target on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating for the company in a report on Friday, September 25th. Finally, William Blair set a $33.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, September 28th. Thirteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.34.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.